Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Paola Carolina Torres-Hernández"'
Autor:
José Javier Morales-Núñez, José Francisco Muñoz-Valle, Paola Carolina Torres-Hernández, Jorge Hernández-Bello
Publikováno v:
Vaccines, Vol 9, Iss 12, p 1376 (2021)
The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are usef
Externí odkaz:
https://doaj.org/article/6ab2dec5ee6a4f3d971641e938aee4c5
Autor:
Jorge Hernández-Bello, José Javier Morales-Núñez, Andrea Carolina Machado-Sulbarán, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández, Paulina Balcázar-Félix, Jesús Alberto Gutiérrez-Brito, José Alvaro Lomelí-Nieto, José Francisco Muñoz-Valle
Publikováno v:
Vaccines, Vol 9, Iss 9, p 1047 (2021)
This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response. In a longitudinal assay, 346 people
Externí odkaz:
https://doaj.org/article/98fbb9a0f1594a2f918dbadd1a20588c
Autor:
José Javier Morales-Núñez, José Francisco Muñoz-Valle, Carlos Meza-López, Lin-Fa Wang, Andrea Carolina Machado Sulbarán, Paola Carolina Torres-Hernández, Martín Bedolla-Barajas, Brenda De la O-Gómez, Paulina Balcázar-Félix, Jorge Hernández-Bello
Publikováno v:
Vaccines, Vol 9, Iss 7, p 742 (2021)
The main expected result of a vaccine against viruses is the ability to produce neutralizing antibodies. Currently, several vaccines against SARS-CoV-2 are being applied to prevent mortal complications, being Pfizer-BioNTech (BNT162b2) one of the fir
Externí odkaz:
https://doaj.org/article/9a7a8959a26a43a6b9770e5f6e4f8829
Autor:
José Javier Morales-Núñez, José Francisco Muñoz-Valle, Andrea Carolina Machado-Sulbarán, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández, Beatriz Verónica Panduro-Espinoza, Jonathan Adrián Gallegos-Díaz de Leon, Carlos David Munguía-Ramirez, Jorge Hernández-Bello
Publikováno v:
Immunology letters.
Neutralizing antibodies (NAbs) can be indicators of collective immunity, vaccine efficacy, and the longevity of the humoral response. This study aimed to compare reactogenicity and NAbs generated by three different COVID-19 vaccine platforms in indiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d556f8b5b2415243cab867e01beff674
https://pubmed.ncbi.nlm.nih.gov/36279685
https://pubmed.ncbi.nlm.nih.gov/36279685
Autor:
José Javier Morales-Núñez, Mariel García-Chagollán, José Francisco Muñoz-Valle, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández, Saraí Citlalic Rodríguez-Reyes, Guillermo Santoscoy-Ascencio, José Julio Sierra García de Quevedo, Jorge Hernández-Bello
Publikováno v:
Journal of inflammation research. 15
José Javier Morales-Núñez,1 Mariel GarcÃa-Chagollán,1 José Francisco Muñoz-Valle,1 Saúl Alberto DÃaz-Pérez,1 Paola Carolina Torres-Hernández,2 Saraà Citlalic RodrÃguez-Reyes,3 Guillermo Santoscoy-Ascencio,4 Jos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18cd8aee25aabb8987425985aff0e124
https://pubmed.ncbi.nlm.nih.gov/35958186
https://pubmed.ncbi.nlm.nih.gov/35958186
Autor:
Paulina Balcázar-Félix, José Javier Morales-Núñez, Jorge Hernández-Bello, José Francisco Muñoz-Valle, Andrea Carolina Machado-Sulbaran, Jesús Alberto Gutiérrez-Brito, José Alvaro Lomelí-Nieto, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández
Publikováno v:
Vaccines
Vaccines, Vol 9, Iss 1047, p 1047 (2021)
Vaccines; Volume 9; Issue 9; Pages: 1047
Vaccines, Vol 9, Iss 1047, p 1047 (2021)
Vaccines; Volume 9; Issue 9; Pages: 1047
This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response. In a longitudinal assay, 346 people
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fefb485e1899ac4f399878b00f5f347c
https://pubmed.ncbi.nlm.nih.gov/34579284
https://pubmed.ncbi.nlm.nih.gov/34579284
Autor:
Jorge Hernández-Bello, Carlos Meza-López, Paola Carolina Torres-Hernández, Brenda De la O-Gómez, Martín Bedolla-Barajas, José Javier Morales-Núñez, José Francisco Muñoz-Valle, Lin-Fa Wang, Andrea Carolina Machado Sulbarán, Paulina Balcázar-Félix
Publikováno v:
Vaccines
Volume 9
Issue 7
Vaccines, Vol 9, Iss 742, p 742 (2021)
Volume 9
Issue 7
Vaccines, Vol 9, Iss 742, p 742 (2021)
The main expected result of a vaccine against viruses is the ability to produce neutralizing antibodies. Currently, several vaccines against SARS-CoV-2 are being applied to prevent mortal complications, being Pfizer-BioNTech (BNT162b2) one of the fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f5fece3064d6436f9e7a7e883fa8f60
http://europepmc.org/articles/PMC8310237
http://europepmc.org/articles/PMC8310237
Autor:
Paola Carolina Torres-Hernández, Jorge Hernández-Bello, José Javier Morales-Núñez, José Francisco Muñoz-Valle
Publikováno v:
Vaccines, Vol 9, Iss 1376, p 1376 (2021)
Vaccines
Vaccines
The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are usef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53ed5596cac12ac9694f7fc1d38bc3e1
https://doi.org/10.3390/vaccines9121376
https://doi.org/10.3390/vaccines9121376